Autoimmune pancreatitis type 2

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:280315K86.1
Who is this for?
Show terms as
1Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Autoimmune pancreatitis type 2 (AIP type 2), also known as idiopathic duct-centric pancreatitis (IDCP) or granulocytic epithelial lesion (GEL)-positive pancreatitis, is a rare inflammatory disorder of the pancreas. Unlike autoimmune pancreatitis type 1, which is part of the systemic IgG4-related disease spectrum, AIP type 2 is a pancreas-specific condition characterized by neutrophilic infiltration of the pancreatic duct epithelium (granulocytic epithelial lesions) without elevated serum IgG4 levels. It primarily affects the exocrine pancreas, leading to pancreatic enlargement, ductal narrowing, and impaired pancreatic function. Patients typically present with obstructive jaundice, abdominal pain, and acute pancreatitis. AIP type 2 tends to affect younger individuals compared to type 1, often presenting in the fourth to fifth decade of life, and affects males and females equally. A notable clinical association exists with inflammatory bowel disease (IBD), particularly ulcerative colitis, which is found in a significant proportion of patients. Unlike type 1, AIP type 2 does not typically involve other organs and serum autoantibody markers are generally absent, making diagnosis more challenging and often requiring histological confirmation through biopsy or surgical resection specimens. Treatment for AIP type 2 centers on corticosteroid therapy, which is highly effective in inducing remission. Most patients respond well to an initial course of oral corticosteroids such as prednisone, with gradual tapering over several weeks. A key advantage of AIP type 2 over type 1 is its significantly lower relapse rate; recurrence after successful steroid treatment is uncommon. In cases where the disease mimics pancreatic cancer on imaging, accurate diagnosis is critical to avoid unnecessary surgical resection. Long-term prognosis is generally favorable with appropriate treatment, though monitoring for associated inflammatory bowel disease is recommended.

Also known as:

Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Autoimmune pancreatitis type 2.

View clinical trials →

No actively recruiting trials found for Autoimmune pancreatitis type 2 at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Autoimmune pancreatitis type 2 community →

Specialists

1 foundView all specialists →
AM
Arezou Khosroshahi, MD
ATLANTA, GA
Specialist
PI on 1 active trial1 Autoimmune pancreatitis type 2 publication

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Autoimmune pancreatitis type 2.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Autoimmune pancreatitis type 2Forum →

No community posts yet. Be the first to share your experience with Autoimmune pancreatitis type 2.

Start the conversation →

Latest news about Autoimmune pancreatitis type 2

No recent news articles for Autoimmune pancreatitis type 2.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Autoimmune pancreatitis type 2

What is Autoimmune pancreatitis type 2?

Autoimmune pancreatitis type 2 (AIP type 2), also known as idiopathic duct-centric pancreatitis (IDCP) or granulocytic epithelial lesion (GEL)-positive pancreatitis, is a rare inflammatory disorder of the pancreas. Unlike autoimmune pancreatitis type 1, which is part of the systemic IgG4-related disease spectrum, AIP type 2 is a pancreas-specific condition characterized by neutrophilic infiltration of the pancreatic duct epithelium (granulocytic epithelial lesions) without elevated serum IgG4 levels. It primarily affects the exocrine pancreas, leading to pancreatic enlargement, ductal narrowin

How is Autoimmune pancreatitis type 2 inherited?

Autoimmune pancreatitis type 2 follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Autoimmune pancreatitis type 2 typically begin?

Typical onset of Autoimmune pancreatitis type 2 is adult. Age of onset can vary across affected individuals.

Which specialists treat Autoimmune pancreatitis type 2?

1 specialists and care centers treating Autoimmune pancreatitis type 2 are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.